test Browse by Author Names Browse by Titles of Works Browse by Subjects of Works Browse by Issue Dates of Works
       

Advanced Search
Home   
 
Browse   
Communities
& Collections
  
Issue Date   
Author   
Title   
Subject   
 
Sign on to:   
Receive email
updates
  
My Account
authorized users
  
Edit Profile   
 
Help   
About T-Space   

T-Space at The University of Toronto Libraries >
University of Toronto at Scarborough >
Bioline International Legacy Collection >
Bioline International Legacy Collection >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1807/7561

Title: LONG TERM ORAL ETOPOSIDE AS SECOND-LINE THERAPY IN RECURRENT EPITHELIAL CARCINOMA OF THE OVARY
Authors: Moosavi, Azam Sadat
Tehranian, Afsaneh
Behtash, Nadereh
Gilani, Mitra Modares
Ghaem-Maghami, Fatemeh
Keywords: Oral etoposide, recurrent epithelial ovarian cancer, second-line chemotherapy.
Issue Date: 31-Dec-2005
Publisher: National Research Centre of Medical Sciences of I.R. IRAN
Citation: Medical Journal of The Islamic Republic of Iran (ISSN: 1016-1430) Vol 19 Num 2
Abstract: Background: The activity and toxicity of etoposide in women with recurrent ovarian cancer was evaluated in a case series of women with recurrent ovarian cancer who had measurable disease. Methods: All patients had prior platinum-based chemotherapy and developed progressive disease. Etoposide was given as 50mg/day for 21 days every 4 weeks until progression of disease or prohibitive toxicity. Between December 1999 and January 2004, 32 patients were enrolled in this study. Results: 30 patients received a total of 133 cycles of etoposide. Median age was 49 years (range, 19 to 75). The median number of etoposide cycles was 4 (range, 1 to 12). There were 5 partial responses (16.6%). The mean response duration was 4.8 months (range, 3.5 to 6), median progression-free interval (PFI) was 7 months (range, 3 to 13), and median survival time was 12.5 months (range, 1.3 to 36). Conclusion: The major toxicity was leukopenia. One patient required red blood cell transfusions, and the main non-hematologic toxicity was nausea and vomiting. There were no treatment-related mortalities. Although etoposide appears to exhibit modest activity in recurrent ovarian cancer after platinum-based therapy, response and survival durations are short.
URI: http://hdl.handle.net/1807/7561
Other Identifiers: http://www.bioline.org.br/abstract?id=mr05011
Rights: Copyright 2005 -Medical Journal of the Islamic Republic of Iran
Appears in Collections:Bioline International Legacy Collection

Files in This Item:

File Description SizeFormat
mr05011.pdf284.88 kBAdobe PDF
View/Open

Items in T-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

uoft